Abstract:1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People’s Republic of China; 2Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, Hangzhou 310003, Zhejiang, People’s Republic of China; 3Key Laboratory of Organ Transplantation, Hangzhou 310003, Zhejiang, People’s Republic of China; 4Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou 310058, Zhejiang, People’s Republic of China; 5Collaborative Innovation Center for Diagnosis Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang, People’s Republic of China Background: Cholangiocarcinoma (CCA) is a subtype of highly malignant hepatic tumor, which has low 5-year survival rate and poor clinical outcome. Only a few patients can be detected early and accepted with the surgery. Most of CCA patients are diagnosed in

Ott_a_253730 10707..10719

Ott_a_231052 11033..11044

Ott_a_286600 12777..12786

Ott_a_222189 10165..10175

Ott_a_273823 1007..1020

Ott_a_203342 8355..8365

Ott_a_218125 8095..8104

Ott_a_280535 12163..12168

Ott_a_218524 8319..8328

Ott_a_252929 5845..5855

Ott_a_227644 389..399

Ott_a_234517 253..261

Ott_a_225596 9385..9393

Ott_a_228746 10469..10475

Ott_a_221589 8587..8594

Ott_a_217794 8947..8954

Ott_a_206448 4755..4763

Ott_a_210376 7513..7525

Ott_a_222223 7591..7599

Ott_a_242517 1757..1765

Ott_a_249063 4943..4956